Compare Revvity Inc (RVTY) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Revvity Inc trades at $152.05 (market cap $16.98B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: Revvity Inc is far larger — about 2.4× Invesco S&P 500 Low Volatility ETF's market cap, and Revvity Inc pays a 0.18% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| RVTY | SPLV | |
|---|---|---|
Market Cap | $16.98B | $6.94B |
Volume | 1,456,900 | 1,663,703 |
Sector | Health | — |
52-Week High | $157.36 | $77.97 |
52-Week Low | $82.26 | $70.30 |
Typical Hold Time | 12 Days | 123 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
SPLV trades at $71.22, down 0.71% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $72. Recent news highlights sector overweights in Utilities and Real Estate as headwinds, with the fund lagging the S&P 500's performance. Dividend payments of $0.14 are scheduled for July and September 2026.
Outlook remains cautious due to technical weakness and unappealing growth-adjusted valuation. Risks include concentrated sector exposure and macroeconomic pressures. The fund's low-volatility strategy may appeal during market uncertainty, but current technicals suggest limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
